ArticleThe oncologist2016
Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.
Article in The oncologist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Quality of Life in Slovak Breast Cancer Survivors: A Cross-Sectional Study Using EORTC QLQ-C30 and BR23.Nursing reports (Pavia, Italy) · 2026Article
- Global burden of lung cancer attributable to secondhand smoke (1990-2021) and predictive trends to 2035.Medicine · 2026Article
- Complementary therapies in early breast cancer: Oncologists' evidence-based decisions in a Southeast European vignette survey.Biomolecules & biomedicine · 2025Article
- The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances.Biomolecules & biomedicine · 2025Review
- Article
- Analysis of the European Union's National Cancer Control Programs: Meeting the Needs of People with Intellectual Disabilities.Healthcare (Basel, Switzerland) · 2025Review
- Advances in nutritional interventions for coronary heart disease patients from the perspective of the gut-heart axis.Frontiers in nutrition · 2025Review
- Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective.The Lancet regional health. Europe · 2024Review
- The Global, Regional, and National Burden of Tracheal, Bronchus, and Lung Cancer Caused by Smoking: An Analysis Based on the Global Burden of Disease Study 2021.Annals of global health · 2024Article
- Perspectives for Cancer Care and Research in Central and Eastern Europe.Oncology research and treatment · 2023Review
- Real-World Patterns and Decision Drivers of Radiotherapy for Lung Cancer Patients in Romania: RADIO-NET Study Results.Diagnostics (Basel, Switzerland) · 2022Article
- The state of gynecologic radiation therapy in low- and middle-income countries.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2022Review
- Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Real-World Data from an Academic Central and Eastern European Center.The oncologist · 2021Observational
- COVID-19 Pandemic Effects on Breast Cancer Diagnosis in Croatia: A Population- and Registry-Based Study.The oncologist · 2021Article
- Advancing Breast Cancer Advocacy in Eastern Europe and Central Asia: Findings From Women's Empowerment Cancer Advocacy Network (WE CAN) Summits.JCO global oncology · 2021Article
- Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
- Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe.Breast (Edinburgh, Scotland) · 2021Review
- Lung cancer biomarker testing: perspective from Europe.Translational lung cancer research · 2020Review
- Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis.The oncologist · 2020Article
- A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries.Frontiers in public health · 2020Article
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
: The incidence of many cancers is higher in Western European (WE) countries, but mortality is frequently higher in Central and Eastern European (CEE) countries. A panel of oncology leaders from CEE countries participating in the South Eastern European Research Oncology Group (SEEROG) was formed in 2015, aiming to analyze the current status and trends of oncology care in CEE and to propose recommendations leading to improved care and outcomes. The SEEROG panel, meeting during the 11th Central European Oncology Congress, proposed the following: (a) national cancer control plans (NCCPs) required in all CEE countries, defining priorities in cancer care, including finance allocation considering limited health care budgets; (b) national cancer registries, describing in detail epidemiological trends; (c) efforts to strengthen comprehensive cancer centers; (d) that multidisciplinary care should be mandated by the NCCPs; (e) that smaller hospitals should be connected to multidisciplinary tumor boards via the Internet, providing access to specialized expertise; (f) nationwide primary prevention programs targeting smoking, obesity, and alcohol consumption and centrally evaluated secondary prevention programs for cervical, colorectal, and breast cancers; (g) prioritize education for all involved in cancer care, including oncology nurses, general practitioners, and palliative care providers; (h) establish outpatient care in day hospitals to reduce costs associated with the current inpatient model of care in CEE countries and to improve patients' quality of life; (i) long-term pharmacoeconomic evaluations of new therapies in CEE countries; (j) increase national oncology budgets in view of the higher mortality rates in CEE compared with WE countries; and (k) CEE countries urgently need help from the European Union to increase and monitor overall investment in cancer care. IMPLICATIONS FOR PRACTICE: Significant differences in cancer incidence and mortality have been observed between European countries. While the incidence of many cancer types is higher in Western European (WE) countries, the mortality is generally higher in Central and Eastern Europe (CEE). The primary purpose of this review was to describe the current status and trends of oncology care in the CEE region, to raise awareness among physicians, regulators, and payers, and to propose the most needed changes in order to make the oncology care in CEE closer to the WE standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.